Table of contents

01 - Pre-meeting briefing document prepared by NICE
02 - Assessment Report prepared by Centre for Reviews and Dissemination, Centre for Health Economics, University of York
03 - Addendum prepared by Centre for Reviews and Dissemination, Centre for Health Economics, University of York
04 - Comments on the Assessment Report - AbbVie
05 - Comments on the Assessment Report model - AbbVie
06 - Comments on the Assessment Report - Celltrion
07 - Comments on the Assessment Report - Health Improvement Scotland
08 - Comments on the Assessment Report - Merck Sharp and Dohme
09 - Comments on the Assessment Report - National Ankylosing Spondylitis Society
10 - Comments on the Assessment Report - NICE spondyloarthritis Guideline Development Group
11 - Comments on the Assessment Report - Pfizer
12 - Comments on the Assessment Report - UCB
13 - Consultee submission - Abbvie
14 - Consultee submission - Merck Sharpe and Dohme - Remicade
15 - Consultee submission - Merck Sharpe and Dohme - Simponi
16 - Consultee submission - Pfizer
17 - Consultee submission - UCB
18 - Consultee submission - British Society of Rheumatology
19 - Consultee submission - National Ankylosing Spondylitis Society
20 - Consultee submission - National Ankylosing Spondylitis Society - survey
21 - Clinical expert personal perspective - Gaffney
22 - Clinical expert personal perspective - Sengupta
23 - Patient expert personal perspective - Cook
24 - Patient expert personal perspective - Stevens